Joint primary and secondary care study of lithium prescribing and monitoring-Reference-Cited by-同舟云学术

Joint primary and secondary care study of lithium prescribing and monitoring

Published:2024-01 Issue:1 Volume:28 Page:17-21
ISSN:1367-7543
Container-title:Progress in Neurology and Psychiatry
language:en
Short-container-title:Prog Neurol Psychiatry

Author:

Vekaria Seema¹,Shah Chetan²,Gale Tim³,Geeson Cathy⁴,Davis Maxine⁵,Weir Janet⁶,Singh Promilla⁷

Affiliation:

1. Seema Vekaria is Lead Clinical Pharmacist at Hertfordshire Partnership University NHS Foundation Trust (HPFT) UK

2. Dr Shah is Research Strategy Operational Lead at Hertfordshire Partnership University NHS Foundation Trust (HPFT) UK

3. Professor Gale is Research Lead at Hertfordshire Partnership University NHS Foundation Trust (HPFT) UK

4. Dr Geeson is Lead Pharmacist – Strategy and Pharmacy Workforce Development, at Hertfordshire and West Essex ICB UK

5. Maxine Davis is Lead Pharmaceutical Advisor, at Hertfordshire and West Essex ICB UK

6. Janet Weir is Senior Pharmaceutical Advisor, at Hertfordshire and West Essex ICB UK

7. Promilla Singh is Pharmaceutical Advisor, at Hertfordshire and West Essex ICB UK

Abstract

Lithium is licensed for the treatment and prophylaxis of mania, bipolar disorder, recurrent depression and intentional self‐harming behaviour. Despite its effectiveness, lithium use is complicated by its narrow therapeutic range. In 2009, the National Patient Safety Agency issued a safety alert highlighting the issues and requested NHS organisations ensure reliable systems and monitoring were in place. This article explores how well the guidelines are followed in terms of lithium prescribing and monitoring across primary and secondary care.

Publisher

Wiley

Reference14 articles.

1. Essential Pharma Ltd. Priadel 200mg prolonged‐release tablets Summary of Product Characteristics (www.medicines.org.uk/emc/product/13162/smpc; accessed 3 January 2024).

2. British National Formulary. Lithium carbonate (https://bnf.nice.org.uk/drugs/lithium-carbonate/#:~:text=For%20all%20lithium%20salts&text=Samples%20should%20be%20taken%2012 maintenance%20therapy%20and%20elderly%20patients; accessed 3 January 2024).

3. HedyaS AkshayA SwobodyH. Lithium Toxicity (www.ncbi.nlm.nih.gov/books/NBK499992; accessed 3 January 2024).

4. Lithium side effects and toxicity: prevalence and management strategies

5. National Patient Safety Agency (NPSA). Patient Safety Alert: Safer Lithium Therapy. (https://webarchive.nationalarchives.gov.uk/ukgwa/20171030130945/http://www.nrls.npsa.nhs.uk/resources/type/alerts/?entryid45=65426&p=2; accessed 3 January 2024).